Biomay AG
09.05.2025 - 12:00
Vienna, Austria (ots) - Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing ...
To the press release of Biomay AG29.04.2025 - 14:00
Vienna (ots) - The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of ...
To the press release of Biomay AG26.01.2024 - 13:50
Vienna (ots) - Biomay, a biotech contract development and manufacturing organization based in Vienna, Austria, announces successful completion of an FDA inspection qualifying Biomay as a cGMP manufacturer and supplier of recombinant nuclease Cas9 ...
To the press release of Biomay AG13.11.2023 - 13:38
Vienna (ots) - Biomay expanded its biomanufacturing facility in central Vienna, 9th district, by adding clean rooms, laboratories, and warehouse premises in the Vienna Competence Center building. Besides the 4000 sqm main site in Vienna 22nd ...
To the press release of Biomay AG 
